ReviewArchives of toxicology2025
An update on the involvement of inflammatory mediators in Parkinson's disease pathogenesis.
Review in Archives of toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- From neuroinflammation to immune reprogramming: Nanozyme-Integrated nanoplatforms for neuroimmune modulation in Parkinson's disease.Materials today. Bio · 2026Article
- Review
- Systemic Endotoxemia, Inflammatory Activation, and Lipid Dysregulation in Parkinson's Disease: Evidence from Circulating LPS-Related Biomarkers and Plasma Lipids.International journal of molecular sciences · 2026Article
- Parkinson's disease: pathogenesis and therapeutic strategies.Molecular biomedicine · 2026Review
- Procoagulant Extracellular Vesicles Increase Neuronal Tau expression, Metabolism and Processing Through Tissue Factor and Protease Activated Receptor 2.Cellular and molecular neurobiology · 2026Article
- Mitophagy-NLRP3 Inflammasome Crosstalk in Parkinson's Disease: Pathogenic Mechanisms and Emerging Therapeutic Strategies.International journal of molecular sciences · 2026Review
- Association of the Naples prognostic score with Parkinson disease risk: a prospective cohort study.Frontiers in aging neuroscience · 2026Article
- Exploring the gut microbiota-Parkinson's disease link: preliminary insights from metagenomics and Mendelian randomization.Frontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several endogenous and exogenous mediators and pathogenic agents trigger inflammation. Despite the brain being less vulnerable to inflammation, many studies have underlined the contribution of inflammatory molecules in the pathogenesis of Parkinson's disease (PD). The onset of the features of PD is the result of an interaction of multiple contributors. These factors include inflammatory mediators, α-synuclein accumulation, oxidative stress, mitochondrial dysfunction, and neuronal cell death. Due to multifaceted interaction and cross-talk amongst a bunch of proteins and pathways, deciphering the aetiology of PD has been quite complex and challenging. It is ambiguous whether inflammatory mediators lead to microglial activation and α-synuclein accumulation or vice versa. It is also unclear how inflammatory mediators cross the peripheral nervous system to the brain and trigger dopaminergic cell death. The present review provides an update on the involvement of inflammatory mediators and non-neuronal cells in dopaminergic cell death, which leads to sporadic PD in humans and PD-like features in rodents. The article emphasises the contribution of inflammatory molecules released from the peripheral nervous system in the selective, progressive, and slow demise of nigrostriatal dopaminergic neuronal cells of the midbrain. The article also narrates the challenges and future perspectives.
Indexed as
Identifiers
40461681What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.